Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Research Grants 2 show all


$436K
2011

Patents 209show all

  • 79
    A61K - Preparations for medical, dental, or toilet purposes
  • 30
    C07D - Heterocyclic compounds
  • 8
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 4
    B82Y - Specific uses or applications of nanostructures
  • 3
    C07B - General methods of organic chemistry
  • 3
    C07C - Acyclic or carbocyclic compounds
  • 3
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 2
    C08G - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds

Clinical Trials 9show all

6Phase 32Phase 21N/A

SEC Filings show all


37
8-K

9
10-Q

7
D

3
10-K

1
S-1

Contact Information

100 Beaver St. Suite 201
Waltham, MA 02453
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$114,243,205101-2502016-04-13Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2009-12-24$2,000,000Series A
2014-04-23$22,500,000Series BYsios CapitalThird Rock Ventures, Crown Venture Fund, Polaris Partners, AbbVie Biotech Ventures, Lux Capital
2013-02-28$11,500,000Series ACrown Venture FundPolaris Partners, Lux Capital, Third Rock Ventures
2016-04-13$68,000,000Series CLongitude CapitalVivo Capital, CAM Capital, Polaris Partners, Lux Capital, RA Capital Management, Wellington Management
2010-11-10$3,000,000Series Unknown
2012-03-14$7,243,205Private EquityPolaris Partners, Lux Capital, Third Rock Ventures, Lighthouse Capital Partners

SEC Form D Funding Events

DateOfferedSoldType
2014-04-24$22,500,000$22,500,000Equity
2013-02-28$11,500,118$5,750,059Equity
2012-03-14$7,243,205$7,243,205Equity
2010-11-10$3,000,000$3,000,000Equity, Debt
2009-12-23$2,000,001$2,000,001Equity

Key Executives

  • Robert Paull
    Executive Officer, Director, Promoter
  • Robert Langer
    Director
  • Justin Hanes
    Director
  • Kevin Bitterman
    Director
  • Robert Tepper
    Director
  • Peter Courossi
    Executive Officer
  • Kevin Pojasek
    Executive Officer
  • Hongming Chen
    Executive Officer
  • Bernard Gilly
    Director
  • Guillaume Pfefer
    Executive Officer, Director
  • Andrea Franz
    Executive Officer
  • Kim Brazzell
    Executive Officer
  • Howard B. Rosen
    Director